There may not be a safe off-ramp for some taking GLP-1 drugs, study suggests

A recent study published in JAMA Internal Medicine reveals that most individuals who discontinue GLP-1 drugs like tirzepatide experience significant weight regain and a reversal of cardiovascular health benefits. Experts suggest rebranding these drugs as 'weight management' medications, implying they may need to be taken indefinitely. The study found that 82% of participants who stopped the drug regained at least 25% of their lost weight, with corresponding declines in health metrics. A small group of participants did not regain weight, but the reasons remain unclear, highlighting the need for further research on potential off-ramps and the effects of weight fluctuations.